Many or all of the products featured here may be from our partners who compensate us. This doesn't influence our evaluations or reviews. Our opinions are our own. Investing information is for ...
Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...
Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results